This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Blueprint Medicines (BPMC) Q4 Loss Narrows, Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines (BPMC) impresses investors with fourth-quarter earnings and revenue beat.
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails
by Kinjel Shah
AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
Prothena (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Prothena (PRTA) reports a narrower-than-expected Q4 loss, while revenues surpass estimates.
Teva (TEVA) Q4 Earnings In Line, Stock Up as Sales Stabilize
by Zacks Equity Research
Teva Pharmaceutical (TEVA) earnings match estimates but sales beat. Shares rise 9%.
J&J Files Application for Darzalex Label Expansion With FDA
by Zacks Equity Research
J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.
Lilly Reports Disappointing Data on Alzheimer's Candidate
by Zacks Equity Research
Eli Lilly's (LLY) Alzheimer's disease drug, solanezumab, fails to meet primary endpoint in a phase II/III investigator-led study.
Roche Reports Disappointing Data on Alzheimer's Disease Drug
by Zacks Equity Research
Roche's (RHHBY) Alzheimer's disease drug fails to meet primary endpoint in a phase II/III study.
The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony
AbbVie's (ABBV) Q4 Earnings Beat, 2020 View Solid, Stock Up
by Zacks Equity Research
AbbVie (ABBV) beat on earnings in the fourth quarter of 2019 while revenues meet the same. Shares up in pre-market trading following a solid 2020 outlook.
Blueprint Medicines' NDA for Avapritinib Gets Extended Review
by Zacks Equity Research
FDA extends review period for Blueprint Medicines' (BPMC) NDA seeking accelerated approval for avapritinib in fourth-line gastrointestinal stromal tumors by three months.
Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales
by Zacks Equity Research
Seattle Genetics (SGEN) rides high on Q4 earnings and revenue beat.
Top Stock Research Reports for Alphabet, Roche & Amgen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Roche Holding (RHHBY) and Amgen (AMGN).
Can Biotech ETFs Continue to Soar in 2020?
by Neena Mishra
We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.
Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.
Can Humira/Cancer Drugs Help AbbVie (ABBV) Beat Q4 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs are likely to have witnessed strong growth.
Merck's Recarbrio Gets FDA Priority Review for New Indication
by Zacks Equity Research
The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.
Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Opdivo, Revlimid and Eliquis along with the regular top and bottom-line numbers when Bristol-Myers (BMY) reports fourth-quarter results.
Bristol-Myers' Opdivo-Yervoy NSCLC Application in EU Withdrawn
by Zacks Equity Research
Bristol-Myers (BMY) has withdrawn its application in the EU for the Opdivo and Yervoy combo for the treatment of advanced NSCLC based on data from the CheckMate-227 study.
Bayer Seeks FDA Approval for New Formulation of Nifurtimox
by Zacks Equity Research
Bayer (BAYRY) files application to the FDA for the new formulation of nifurtimox to improve the body-weight adjusted dosing in pediatric Chagas patients.
Amgen (AMGN) Stock Down Despite Q4 Earnings & Revenue Beat
by Zacks Equity Research
Amgen (AMGN) stock declines despite better-than-expected fourth-quarter 2019 results. Its 2020 earnings guidance falls short of expectations.
Lilly's NDA for Selpercatinib Gets FDA's Priority Review
by Zacks Equity Research
Lilly's (LLY) NDA for oral RET inhibitor selpercatinib gains the FDA priority review status for RET-altered lung and thyroid cancers.
Biogen (BIIB) Surpasses Q4 Earnings and Sales Estimates
by Zacks Equity Research
Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The company expects decline in sales and earnings in 2020.
Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance in 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
Novartis (NVS) Earnings and Revenues Miss Estimates in Q4
by Zacks Equity Research
Novartis (NVS) reports disappointing results for the fourth quarter but provides an encouraging outlook for 2020.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
Biogen's (BIIB) fourth-quarter MS franchise sales are expected to have been flat. Spinraza U.S. sales are expected to have been supported by continued patient growth.